U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
134361
Substance Class Structurally Diverse
Created
by admin
on Thu Jul 06 21:12:06 UTC 2023
Edited
by admin
on Thu Jul 06 21:12:06 UTC 2023
Source Materials Class ORGANISM
Source Materials Type VIRUS
Source Materials State LIVE
Organism Family Coronaviridae
Organism Genus Betacoronavirus
Organism Species severe acute respiratory syndrome-related coronavirus
Author NONE
Infraspecific Type STRAIN
Infraspecific Name SARS-CoV-2
Part WHOLE
Record UNII
B6L4N5Z4GH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SARS-COV-2
Common Name English
COVID-19
Common Name English
2019-NCOV
Common Name English
SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2
Common Name English
Code System Code Type Description
FDA UNII
B6L4N5Z4GH
Created by admin on Thu Jul 06 21:12:08 UTC 2023 , Edited by admin on Thu Jul 06 21:12:08 UTC 2023
PRIMARY
Related Record Type Details
CILGAVIMAB
INHIBITOR->TARGET ORGANISM
Structure of BRILACIDIN
INHIBITOR->TARGET ORGANISM
CORONAVAC ANTIGEN ADJUVATED WITH ALUM
VACCINE ANTIGEN->TARGET ORGANISM
On February 5, 2021 Sinovac announced data from a 12,396-participant, Phase III trial in Brazil and Turkey showing CoronaVac to be 100% effective in preventing death or hospitalization in patients with COVID-19, 83.7% effective in avoiding cases that required any medical treatment, but just 50.65% effective at preventing infection with the virus.
EFFICACY
CIGB-66
VACCINE ANTIGEN->TARGET
Structure of FAVIPIRAVIR
INHIBITOR->TARGET ORGANISM
DRUG APPROVED IN CHINA FOR COVID-19. Prodrug that InhibitS the RNA-dependent RNA polymerase after activation to triphosphate.
Structure of RIBAVIRIN
INHIBITOR->TARGET ORGANISM
A guanine derivative approved for treating HCV and respiratory syncytial virus (RSV) that has been evaluated in patients with SARS and MERS, but its side effects such as anaemia may be severe at high doses.
Structure of UMIFENOVIR
INHIBITOR->TARGET ORGANISM
VIXICOVTOGENE OBOPLASMID
VACCINE ANTIGEN->TARGET ORGANISM
Structure of REMDESIVIR
INHIBITOR->TARGET ORGANISM
In Vero E6 cells inhibits. Targets the RNA-dependent RNA polymerase and block viral RNA synthesis in a broad spectrum of RNA viruses, including human coronaviruses. A US patient with 2019-nCoV recovered after receiving intravenous remdesivir in January
BIOASSAY (CELLULAR)
EC50
Gorivitug
INHIBITOR->TARGET ORGANISM
ADINTREVIMAB
INHIBITOR->TARGET ORGANISM
Structure of Ensitrelvir
INHIBITOR->TARGET ORGANISM
ENUZOVIMAB
INHIBITOR->TARGET ORGANISM
SARS-COV-2
INHIBITOR->TARGET ORGANISM
SPIKE GLYCOPROTEIN (SARS-COV-2) (339-347)
VACCINE ANTIGEN->TARGET ORGANISM
Structure of VR17-04
INHIBITOR->TARGET ORGANISM
UPANOVIMAB
INHIBITOR->TARGET ORGANISM
IN-VITRO
CX-037073
VACCINE ANTIGEN->TARGET ORGANISM
SARS-COV-2 CN2 STRAIN .BETA.-PROPIOLACTONE INACTIVATED VACCINE ANTIGEN
VACCINE ANTIGEN->TARGET ORGANISM
BAMLANIVIMAB
INHIBITOR->TARGET ORGANISM
The antibody binds selectively to the spike protein of SARS-CoV-2.
47D11
INHIBITOR->TARGET ORGANISM
Ufrenmeran
VACCINE ANTIGEN->TARGET
AZD-1222
VACCINE ANTIGEN->TARGET ORGANISM
One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%. no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. There were a total of 131 COVID-19 cases in the interim analysis
EFFICACY
Imelasomeran
INHIBITOR -> TARGET
INM-005
INHIBITOR->TARGET ORGANISM
Carocovatein
VACCINE ANTIGEN->TARGET ORGANISM
BBV-152 ANTIGEN
VACCINE ANTIGEN->TARGET
HUMAN ANTI-SARS-COV-2 IMMUNOGLOBULIN
INHIBITOR -> TARGET
PIDACMERAN
VACCINE ANTIGEN->TARGET ORGANISM
CVXGA1
VACCINE ANTIGEN->TARGET
Structure of NITAZOXANIDE
INHIBITOR->TARGET ORGANISM
In Vero E6 cells
EC50
Structure of RIAMILOVIR
INHIBITOR->TARGET ORGANISM
Structure of ABIMTRELVIR
INHIBITOR->TARGET ORGANISM
Structure of CAMOSTAT
INHIBITOR->TARGET ORGANISM
nother in vitro study showed that Camostat reduces significantly the infection of Calu-3 lung cells by SARS-CoV-2, the virus responsible for COVID-19.[9]
RIMTERAVIMAB
INHIBITOR->TARGET ORGANISM
Zeldesmeran
VACCINE ANTIGEN->TARGET
SARS-COV-2 WIV04 STRAIN .BETA.-PROPIOLACTONE INACTIVATED VACCINE ANTIGEN
VACCINE ANTIGEN->TARGET ORGANISM
COVID-19 CONVALESCENT PLASMA
INHIBITOR -> TARGET
DVX-201
INHIBITOR->TARGET ORGANISM
AZD-3152
INHIBITOR->TARGET ORGANISM
SPIKE GLYCOPROTEIN (SARS-COV-2) (336-350)
VACCINE ANTIGEN->TARGET ORGANISM
ETESEVIMAB
INHIBITOR->TARGET ORGANISM
Structure of SIMPINICLINE
INHIBITOR -> TARGET
SARS-COV2 B.1.1.529 VARIANT
INFRASPECIFIC -> PARENT ORGANISM
BNT162b2 Omicron (XBB.1.5)
VACCINE ANTIGEN->TARGET ORGANISM
CX-036651
VACCINE ANTIGEN->TARGET ORGANISM
TIXAGEVIMAB
INHIBITOR->TARGET ORGANISM
Structure of Nirmatrelvir
INHIBITOR->TARGET ORGANISM
Differentiated normal human bronchial epithelial (dNHBE) cells
EC90
SOTROVIMAB
INHIBITOR->TARGET ORGANISM
R-AD5-S (RECOMBINANT ADENOVIRUS TYPE 5 CARRYING THE GENE FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE GLYCOPROTEIN)
VACCINE ANTIGEN->TARGET ORGANISM
Structure of DARAPLADIB
INHIBITOR->TARGET ORGANISM
Simaravibart
INHIBITOR->TARGET ORGANISM
Tozinameran
VACCINE ANTIGEN->TARGET ORGANISM
From 7 days after second dose to a median time of 2 months.
EFFICACY
ZORECIMERAN
VACCINE ANTIGEN->TARGET ORGANISM
ORF1AB POLYPROTEIN (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2)
PART/FRACTION -> PARENT ORGANISM
Structure of JNJ-5207852
INHIBITOR->TARGET ORGANISM
Structure of HYDROXYCHLOROQUINE
INHIBITOR->TARGET ORGANISM
after 24 hours incubation; works in cell culture may not work in-vivo
EC50
Structure of GENZ-123346
INHIBITOR->TARGET ORGANISM
AD26.COV2.S
VACCINE ANTIGEN->TARGET ORGANISM
REGDANVIMAB
INHIBITOR->TARGET ORGANISM
AMUBARVIMAB
INHIBITOR->TARGET ORGANISM
CX-038839 Omicron (XBB.1.5)
VACCINE ANTIGEN->TARGET ORGANISM
ROMLUSEVIMAB
INHIBITOR->TARGET ORGANISM
SAB-185
INHIBITOR->TARGET ORGANISM
ABDAVOMERAN
VACCINE ANTIGEN->TARGET ORGANISM
Structure of GS-441524
INHIBITOR->TARGET ORGANISM
Structure of LUFOTRELVIR
INHIBITOR->TARGET ORGANISM
Zapomeran
VACCINE ANTIGEN->TARGET
Structure of PF-07329268
INHIBITOR->TARGET ORGANISM
Epithelial Vero E6 cells; EC50 Nirmatrelvir = 74.5
ELASOMERAN
VACCINE ANTIGEN->TARGET ORGANISM
CASIRIVIMAB
INHIBITOR->TARGET ORGANISM
CX-039300
VACCINE ANTIGEN->TARGET ORGANISM
MASAVIBART
INHIBITOR->TARGET ORGANISM
Structure of GALIDESIVIR
INHIBITOR->TARGET ORGANISM
Has shown antiviral activities in preclinical studies against many RNA viruses, including SARS and MERS.
R-AD26-S (RECOMBINANT ADENOVIRUS TYPE 26 CARRYING THE GENE FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE GLYCOPROTEIN)
VACCINE ANTIGEN->TARGET ORGANISM
Structure of N4-HYDROXYCYTIDINE
INHIBITOR->TARGET ORGANISM
ENSOVIBEP
INHIBITOR->TARGET ORGANISM
NVX-COV2373
VACCINE ANTIGEN->TARGET ORGANISM
GANULAMERAN
VACCINE ANTIGEN->TARGET ORGANISM
Structure of CHLOROQUINE
INHIBITOR->TARGET ORGANISM
In Vero E6 cells
EC50
Structure of MOLNUPIRAVIR
INHIBITOR->TARGET ORGANISM
SARS-COV-2 CN2 STRAIN .BETA.-PROPIOLACTONE INACTIVATED VACCINE ANTIGEN
TARGET ORGANISM->VACCINE ANTIGEN
AGAINST COVID DISEASE
EFFICACY
NEPUVIBART
INHIBITOR->TARGET ORGANISM
Famtozinameran
VACCINE ANTIGEN->TARGET ORGANISM
AD5-NCOV
VACCINE ANTIGEN->TARGET ORGANISM
Structure of GS-621763
INHIBITOR->TARGET ORGANISM
CX-040631 Omicron (XBB.1.16)
VACCINE ANTIGEN->TARGET ORGANISM
PLUTAVIMAB
INHIBITOR->TARGET ORGANISM
IN-VITRO
Structure of RUPINTRIVIR
INHIBITOR->TARGET ORGANISM
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966